Vadim Koshkin, MD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Address550 16th Street, #6811
San Francisco CA 94158
ORCID ORCID Icon0000-0003-2277-8668 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Pennsylvania, Philadelphia, PABA05/2007Cognitive Science
    University of Chicago, Pritzker School of Medicine, Chicago, ILMD06/2012Medicine
    University of Michigan, Ann Arbor, MI06/2015Internal Medicine Residency
    Cleveland Clinic, Cleveland, OH06/2018Hematology/Oncology Fellowship
    Collapse Awards and Honors
    Prostate Cancer Foundation2021  - 2024Young Investigator Award
    National Cancer Institute 2020  - 2022NIH Loan Repayment Program (LRP) Grant
    Hellen Diller Family Comprehensive Cancer Center at UCSF2019  - 2020Junior Clinical Investigator Award
    Bladder Cancer Advocacy Network (BCAN)2017John Quale Travel Fellowship Award
    Kidney Cancer Association2017Young Investigator Abstract Award
    Conquer Cancer Foundation2017Abstract Merit Award
    AACR/ASCO2016Methods in Clinical Cancer Research Workshop Participant
    Conquer Cancer Foundation 2015Abstract Merit Award

    Collapse Overview 
    Collapse Overview
    I am a genitourinary medical oncologist and in this capacity I specialize in caring for patients with bladder, prostate, kidney and testicular cancers. My focus is in clinical and translational research in bladder and prostate cancers, in particular the design and implementation of clinical trials for patients with these malignancies and the discovery and validation of novel biomarkers and treatment targets.

    Collapse Research 
    Collapse Research Activities and Funding
    Using CDK 4/6 Inhibition to Augment PSMA Expression in Advanced Prostate Cancer and Enhance Clinical Responses to PSMA-Targeted Radioligand Therapy
    Prostate Cancer Foundation 20YOUN07Jan 4, 2021 - Jan 3, 2024
    Role: Principal Investigator
    Description: First in human clinical trial of CDK4 inhibitor followed by 177Lu-PSMA-617 in patients with advanced prostate cancer.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10). Urol Oncol. 2024 Oct 29. Siefker-Radtke AO, Huddart RA, Bilen MA, Balar A, Castellano D, Sridhar SS, De Giorgi U, Penkov K, Vasiliev A, Peer A, Järvinen R, Harputluoglu H, Koshkin VS, Poushnejad S, Wang T, Qureshi A, Tagliaferri MA, Zalevsky J, Loriot Y. PMID: 39477771.
      View in: PubMed   Mentions:    Fields:    
    2. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor. Clin Genitourin Cancer. 2024 Aug 12; 22(6):102198. Bakaloudi DR, Talukder R, Makrakis D, Diamantopoulos L, Enright T, Leary JB, Patgunarajah U, Thomas VM, Swami U, Agarwal N, Jindal T, Koshkin VS, Brown JR, Barata P, Murgic J, Miletic M, Johnson J, Zakharia Y, Hui G, Drakaki A, Duran I, Buznego LA, Barrera RM, Castañeda DM, Rey-Cárdenas M, Castellano D, Nguyen CB, Park JJ, Alva A, McKay RR, Stewart TF, Epstein IB, Bellmunt J, Wright JL, Gupta S, Grivas P, Khaki AR. PMID: 39241315.
      View in: PubMed   Mentions:    Fields:    
    3. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Oncologist. 2024 Aug 05; 29(8):e1094-e1097. Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, Friedlander TW, Koshkin VS. PMID: 38908022; PMCID: PMC11299940.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes. JCO Precis Oncol. 2024 Aug; 8:e2400014. Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT. PMID: 39178368; PMCID: PMC11346579.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    5. Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2024 Jul 17. Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, Kilari D, Thapa B, Piero M, Graham L, Tripathi A, Garje R, Koshkin VS, Hernandez E, Dorff TB, Schweizer MT, Alva AS, McKay RR, Armstrong AJ. PMID: 39019980.
      View in: PubMed   Mentions:    Fields:    
    6. Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection. Front Oncol. 2024; 14:1382582. Yadav S, Kim ST, Tuchayi AM, Jiang F, Morley A, Saelee R, Wang Y, Juarez R, Lawnh-Heath C, Koshkin VS, Hope TA. PMID: 38993644; PMCID: PMC11238039.
      View in: PubMed   Mentions:
    7. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial. Cancer. 2024 Oct 15; 130(20):3426-3435. Morris MJ, de Bono J, Nagarajah J, Sartor O, Wei XX, Nordquist LT, Koshkin VS, Chi KN, Krause BJ, Herrmann K, Rahbar K, Vickers A, Mirante O, Ghouse R, Fizazi K, Tagawa ST. PMID: 39031642.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    8. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape. Eur Urol Focus. 2024 Mar; 10(2):231-233. Brown JR, Koshkin VS. PMID: 38797658.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Therapy Attrition and Lessons for Future Approaches to Treatment of Advanced Urothelial Cancer. JAMA Netw Open. 2024 May 01; 7(5):e249426. Koshkin VS. PMID: 38696174.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. CRE24-034: Successful Management of Locally Advanced and Oligometastatic Urothelial Carcinoma With Pembrolizumab-Based Induction Regimen Followed by Consolidative Radical Resection of the Primary Tumor: A Multi-Institutional Case Series. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5). Jang A, Jindal T, Calaway AC, Shoag JE, Koshkin VS, Barata PC. PMID: 38579747.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations. JCO Precis Oncol. 2024 Apr; 8:e2300567. Park JJ, Chu A, Li J, Ali A, McKay RR, Hwang C, Labriola MK, Jang A, Kilari D, Mo G, Ravindranathan D, Graham LS, Sokolova A, Tripathi A, Pilling A, Jindal T, Ravindra A, Cackowski FC, Sweeney PL, Thapa B, Amery TS, Heath EI, Garje R, Zakharia Y, Koshkin VS, Bilen MA, Schweizer MT, Barata PC, Dorff TB, Cieslik M, Alva AS, Armstrong AJ. PMID: 38579192.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration. Prostate Cancer Prostatic Dis. 2024 Feb 22. Zengin ZB, Henderson NC, Park JJ, Ali A, Nguyen C, Hwang C, Barata PC, Bilen MA, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin VS, Patel VG, Schweizer MT, Armstrong AJ, McKay RR, Alva A, Dorff T. PMID: 38383885.
      View in: PubMed   Mentions: 1     Fields:    
    13. Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer. J Nucl Med. 2024 Feb 01; 65(2):199-205. Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA. PMID: 38212070.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    14. Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma. Cancer Drug Resist. 2023; 6(4):858-873. Sweeney PL, Suri Y, Basu A, Koshkin VS, Desai A. PMID: 38239394; PMCID: PMC10792482.
      View in: PubMed   Mentions: 3  
    15. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy. Eur Urol Oncol. 2024 Aug; 7(4):914-922. Grivas P, Koshkin VS, Chu X, Cole S, Jain RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, Woo B, Li-Ning-Tapia E, Hahn NM, Carducci MA. PMID: 38155060.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    16. Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer. Med. 2024 Feb 09; 5(2):106-108. Zhu X, Koshkin VS. PMID: 38128535.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series. Clin Genitourin Cancer. 2024 04; 22(2):315-321. Shipp C, Jindal T, Chou J, Friedlander TW, Koshkin VS, Kumar V. PMID: 38114390.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023 11; 24(11):1266-1276. Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong L, Hope TA. PMID: 37922930; PMCID: PMC10667020.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    19. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study. Elife. 2023 10 17; 12. Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman LE, Flora DB, Friese CR, Galsky MD, Gonzalez CJ, Grivas P, Gupta S, Haynam M, Heilman H, Hershman DL, Hwang C, Jani C, Jhawar SR, Joshi M, Kaklamani V, Klein EJ, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Kwon DH, Labaki C, Lammers PE, Lathrop KI, Lewis MA, Li X, Lopes GL, Lyman GH, Makower DF, Mansoor AH, Markham MJ, Mashru SH, McKay RR, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen RH, Nonato TK, O'Connor TL, Panagiotou OA, Park K, Patel JM, Patel KG, Peppercorn J, Polimera H, Puc M, Rao YJ, Razavi P, Reid SA, Riess JW, Rivera DR, Robson M, Rose SJ, Russ AD, Schapira L, Shah PK, Shanahan MK, Shapiro LC, Smits M, Stover DG, Streckfuss M, Tachiki L, Thompson MA, Tolaney SM, Weissmann LB, Wilson G, Wotman MT, Wulff-Burchfield EM, Mishra S, French B, Warner JL, Lustberg MB, Accordino MK, Shah DP, COVID-19 and Cancer Consortium. PMID: 37846664; PMCID: PMC10637772.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    20. Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19. JAMA Oncol. 2023 10 01; 9(10):1390-1400. Gulati S, Hsu CY, Shah S, Shah PK, Zon R, Alsamarai S, Awosika J, El-Bakouny Z, Bashir B, Beeghly A, Berg S, de-la-Rosa-Martinez D, Doroshow DB, Egan PC, Fein J, Flora DB, Friese CR, Fromowitz A, Griffiths EA, Hwang C, Jani C, Joshi M, Khan H, Klein EJ, Heater NK, Koshkin VS, Kwon DH, Labaki C, Latif T, McKay RR, Nagaraj G, Nakasone ES, Nonato T, Polimera HV, Puc M, Razavi P, Ruiz-Garcia E, Saliby RM, Shastri A, Singh SRK, Tagalakis V, Vilar-Compte D, Weissmann LB, Wilkins CR, Wise-Draper TM, Wotman MT, Yoon JJ, Mishra S, Grivas P, Shyr Y, Warner JL, Connors JM, Shah DP, Rosovsky RP, COVID-19 and Cancer Consortium. PMID: 37589970; PMCID: PMC10436185.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    21. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2023 09 05; 6(9):e2334208. Hwang C, Henderson NC, Chu SC, Holland B, Cackowski FC, Pilling A, Jang A, Rothstein S, Labriola M, Park JJ, Ghose A, Bilen MA, Mustafa S, Kilari D, Pierro MJ, Thapa B, Tripathi A, Garje R, Ravindra A, Koshkin VS, Hernandez E, Schweizer MT, Armstrong AJ, McKay RR, Dorff TB, Alva AS, Barata PC. PMID: 37721753; PMCID: PMC10507489.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    22. Editorial: Methods in genitourinary oncology. Front Oncol. 2023; 13:1274264. Jang A, Sella A, Nassar AH, Koshkin VS. PMID: 37692849; PMCID: PMC10484602.
      View in: PubMed   Mentions:
    23. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544. Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Lerner SP. PMID: 37596191; PMCID: PMC10869634.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    24. Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration. Res Sq. 2023 Aug 10. Dorff T, Zengin Z, Henderson N, Ali A, Nguyen C, Hwang C, Barata PC, Bilen M, Graham L, Mo G, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A. PMID: 37609284; PMCID: PMC10441451.
      View in: PubMed   Mentions:
    25. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer. Curr Treat Options Oncol. 2023 09; 24(9):1213-1230. Singh A, Osbourne AS, Koshkin VS. PMID: 37428331.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience. Clin Genitourin Cancer. 2023 10; 21(5):584-593. Bakaloudi DR, Talukder R, Lin GI, Makrakis D, Diamantopoulos LN, Tripathi N, Agarwal N, Zakopoulou R, Bamias A, Brown JR, Pinato DJ, Korolewicz J, Jindal T, Koshkin VS, Murgic J, Miletic M, Frobe A, Johnson J, Zakharia Y, Drakaki A, Rodriguez-Vida A, Rey-Cárdenas M, Castellano D, Buznego LA, Duran I, Carballeira CC, Barrera RM, Marmorejo D, McKay RR, Stewart T, Gupta S, Ruplin AT, Yu EY, Khaki AR, Grivas P. PMID: 37414620; PMCID: PMC11289267.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    27. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease. Transl Oncol. 2023 Aug; 34:101709. Moey MYY, Hennessy C, French B, Warner JL, Tucker MD, Hausrath DJ, Shah DP, DeCara JM, Bakouny Z, Labaki C, Choueiri TK, Dent S, Akhter N, Ismail-Khan R, Tachiki L, Slosky D, Polonsky TS, Awosika JA, Crago A, Wise-Draper T, Balanchivadze N, Hwang C, Fecher LA, Gomez CG, Hayes-Lattin B, Glover MJ, Shah SA, Gopalakrishnan D, Griffiths EA, Kwon DH, Koshkin VS, Mahmood S, Bashir B, Nonato T, Razavi P, McKay RR, Nagaraj G, Oligino E, Puc M, Tregubenko P, Wulff-Burchfield EM, Xie Z, Halfdanarson TR, Farmakiotis D, Klein EJ, Robilotti EV, Riely GJ, Durand JB, Hayek SS, Kondapalli L, Berg S, O'Connor TE, Bilen MA, Castellano C, Accordino MK, Sibel B, Weissmann LB, Jani C, Flora DB, Rudski L, Dutra MS, Nathaniel B, Ruíz-García E, Vilar-Compte D, Gupta S, Morgans A, Nohria A, COVID-19 and Cancer Consortium. PMID: 37302348; PMCID: PMC10235676.
      View in: PubMed   Mentions:
    28. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 06; 24(6):597-610. Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. PMID: 37269841; PMCID: PMC10641914.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    29. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer. 2023 10; 21(5):e394-e404. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. PMID: 37316414.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front Oncol. 2023; 13:1161089. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. PMID: 37091148; PMCID: PMC10113661.
      View in: PubMed   Mentions: 5  
    31. Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. medRxiv. 2023 Mar 10. Nagaraj G, Vinayak S, Khaki AR, Sun T, Kuderer NM, Aboulafia DM, Acoba JD, Awosika J, Bakouny Z, Balmaceda NB, Bao T, Bashir B, Berg S, Bilen MA, Bindal P, Blau S, Bodin BE, Borno HT, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman LE, Flora DB, Friese CR, Galsky MD, Gonzalez CJ, Grivas P, Gupta S, Haynam M, Heilman H, Hershman DL, Hwang C, Jani C, Jhawar SR, Joshi M, Kaklamani V, Klein EJ, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Kwon DH, Labaki C, Lammers PE, Lathrop KI, Lewis MA, Li X, de Lima Lopes G, Lyman GH, Makower DF, Mansoor AH, Markham MJ, Mashru SH, McKay RR, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen RH, Nonato TK, O'Connor TL, Panagiotou OA, Park K, Patel JM, Patel KG, Peppercorn J, Polimera H, Puc M, Rao YJ, Razavi P, Reid SA, Riess JW, Rivera DR, Robson M, Rose SJ, Russ AD, Schapira L, Shah PK, Shanahan MK, Shapiro LC, Smits M, Stover DG, Streckfuss M, Tachiki L, Thompson MA, Tolaney SM, Weissmann LB, Wilson G, Wotman MT, Wulff-Burchfield EM, Mishra S, French B, Warner JL, Lustberg MB, Accordino MK, Shah DP. PMID: 37205429; PMCID: PMC10187350.
      View in: PubMed   Mentions:
    32. Laryngeal Mucous Membrane Pemphigoid as an Immune-related Adverse Effect of Pembrolizumab Treatment. J Voice. 2023 Jan 18. Lagos-Villaseca A, Koshkin VS, Kinet MJ, Rosen CA. PMID: 36658034.
      View in: PubMed   Mentions: 1     Fields:    
    33. Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. JAMA Oncol. 2023 01 01; 9(1):128-134. Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK, Wise-Draper TM, COVID-19 and Cancer Consortium. PMID: 36326731; PMCID: PMC9634600.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    34. Editorial: Radical cystectomy in bladder cancer patients. Front Oncol. 2022; 12:1113112. Koshkin VS, Almassi N, Aragon-Ching JB. PMID: 36601472; PMCID: PMC9806984.
      View in: PubMed   Mentions:
    35. Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. Urol Oncol. 2023 03; 41(3):146.e1-146.e11. Langlais CS, Chen YH, Van Blarigan EL, Chan JM, Ryan CJ, Zhang L, Borno HT, Newton RU, Luke A, Bang AS, Panchal N, Tenggara I, Schultz B, Lavaki E, Pinto N, Aggarwal R, Friedlander T, Koshkin VS, Harzstark AL, Small EJ, Kenfield SA. PMID: 36528473.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    36. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urol Oncol. 2023 03; 41(3):145.e7-145.e15. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. PMID: 36435709.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    37. Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2023 04; 21(2):286-294. Makrakis D, Bakaloudi DR, Talukder R, Lin GI, Diamantopoulos LN, Jindal T, Vather-Wu N, Zakharia Y, Tripathi N, Agarwal N, Dawsey S, Gupta S, Lu E, Drakaki A, Liu S, Zakopoulou R, Bamias A, Fulgenzi CM, Cortellini A, Pinato D, Barata P, Grivas P, Khaki AR, Koshkin VS. PMID: 36481176.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    38. Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study. J Immigr Minor Health. 2023 Jun; 25(3):624-633. Borno HT, Kim MO, Tolstykh I, Lin A, Hong JC, Yousefi S, Zhang S, McKay RR, Harismendy O, Razavi P, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ. PMID: 36344859; PMCID: PMC9640901.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    39. HER2 expression in urothelial carcinoma, a systematic literature review. Front Oncol. 2022; 12:1011885. Scherrer E, Kang A, Bloudek LM, Koshkin VS. PMID: 36338710; PMCID: PMC9635895.
      View in: PubMed   Mentions: 16  
    40. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022 12; 20(6):558-567. Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR. PMID: 36155169; PMCID: PMC10233855.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    41. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022 10; 20(5):e440-e452. Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Jang A, Barata P, Sonpavde G, Yu EY, Montgomery RB, Grivas P, Khaki AR. PMID: 35778337; PMCID: PMC10257151.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    42. Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer. 2022 05 19; 8(2):e33859. Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, theMednet.org NCI-CCC Tumor Board Program Collaborative Group, Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. PMID: 35588361; PMCID: PMC9164098.
      View in: PubMed   Mentions:
    43. COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry. Oncologist. 2022 05 06; 27(5):398-406. Borno HT, Kim MO, Hong JC, Yousefi S, Lin A, Tolstykh I, Zhang S, McKay RR, Harismendy O, Cinar P, Rugo H, Koshkin VS, Rabow M, Wang C, Bailey A, Small EJ. PMID: 35348771; PMCID: PMC9074994.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    44. Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood Cancer Discov. 2022 05 05; 3(3):181-193. Rubinstein SM, Bhutani D, Lynch RC, Hsu CY, Shyr Y, Advani S, Mesa RA, Mishra S, Mundt DP, Shah DP, Sica RA, Stockerl-Goldstein KE, Stratton C, Weiss M, Beeghly-Fadiel A, Accordino M, Assouline SE, Awosika J, Bakouny Z, Bashir B, Berg S, Bilen MA, Castellano CA, Cogan JC, Kc D, Friese CR, Gupta S, Hausrath D, Hwang C, Johnson NA, Joshi M, Kasi A, Klein EJ, Koshkin VS, Kuderer NM, Kwon DH, Labaki C, Latif T, Lau E, Li X, Lyman GH, McKay RR, Nagaraj G, Nizam A, Nonato TK, Olszewski AJ, Polimera HV, Portuguese AJ, Puc MM, Razavi P, Rosovski R, Schmidt A, Shah SA, Shastri A, Su C, Torka P, Wise-Draper TM, Zubiri L, Warner JL, Thompson MA, COVID-19 and Cancer Consortium. PMID: 35262738; PMCID: PMC9355598.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    45. Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. Oncologist. 2022 03 11; 27(3):220-227. Freeman MN, Jang A, Zhu J, Sanati F, Nandagopal L, Ravindranathan D, Desai A, Phone A, Nussenzveig R, Jaeger E, Caputo SA, Koshkin VS, Swami U, Basu A, Bilen MA, Agarwal N, Sartor O, Burgess EF, Barata PC. PMID: 35274720; PMCID: PMC8914485.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    46. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. Front Oncol. 2022; 12:816706. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. PMID: 35321431; PMCID: PMC8935010.
      View in: PubMed   Mentions: 7  
    47. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol. 2022 12; 5(6):714-718. Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. PMID: 35216942; PMCID: PMC10262920.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    48. Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. Open Forum Infect Dis. 2022 Mar; 9(3):ofac037. Satyanarayana G, Enriquez KT, Sun T, Klein EJ, Abidi M, Advani SM, Awosika J, Bakouny Z, Bashir B, Berg S, Bernardes M, Egan PC, Elkrief A, Feldman LE, Friese CR, Goel S, Gomez CG, Grant KL, Griffiths EA, Gulati S, Gupta S, Hwang C, Jain J, Jani C, Kaltsas A, Kasi A, Khan H, Knox N, Koshkin VS, Kwon DH, Labaki C, Lyman GH, McKay RR, McNair C, Nagaraj G, Nakasone ES, Nguyen R, Nonato TK, Olszewski AJ, Panagiotou OA, Puc M, Razavi P, Robilotti EV, Santos-Dutra M, Schmidt AL, Shah DP, Shah SA, Vieira K, Weissmann LB, Wise-Draper TM, Wu U, Wu JT, Choueiri TK, Mishra S, Warner JL, French B, Farmakiotis D. PMID: 35198648; PMCID: PMC8860152.
      View in: PubMed   Mentions: 3  
    49. Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. JCO Oncol Pract. 2022 05; 18(5):e648-e658. Kwon DH, Karthikeyan S, Chang A, Borno HT, Koshkin VS, Desai A, Bose R, Friedlander T, Rodvelt T, Li P, Small EJ, Aggarwal RR, Belkora J. PMID: 34932386.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    50. Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clin Genitourin Cancer. 2022 04; 20(2):165-175. Talukder R, Makrakis D, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lorenzo GD, Joshi M, Velho PI, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. PMID: 35078711; PMCID: PMC8995351.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    51. Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series. Clin Genitourin Cancer. 2022 04; 20(2):189-194. Jindal T, Chou J, Friedlander T, Barata PC, Koshkin VS. PMID: 34998700.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2022 Mar 15; 128(6):1194-1205. Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. PMID: 34882781.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    53. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int. 2022 11; 130(5):592-603. Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. PMID: 34597472; PMCID: PMC10257152.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancer. Cancer Med. 2021 11; 10(22):8058-8070. Kenfield SA, Van Blarigan EL, Panchal N, Bang A, Zhang L, Graff RE, Chen YH, Ryan CJ, Luke A, Newton RU, Tenggara I, Schultz B, Wang E, Lavaki E, Zuniga K, Pinto N, Borno H, Aggarwal R, Friedlander T, Koshkin VS, Harzstark A, Small E, Chan JM. PMID: 34636156; PMCID: PMC8607248.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    55. Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review. Transl Androl Urol. 2021 Oct; 10(10):4022-4035. Koshkin VS, Osbourne AS, Grivas P. PMID: 34804845; PMCID: PMC8575584.
      View in: PubMed   Mentions: 1  
    56. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer Prostatic Dis. 2022 09; 25(3):388-396. Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R. PMID: 34363009; PMCID: PMC9385488.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    57. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol. 2021 06 17. Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL, COVID-19 and Cancer Consortium. PMID: 34137799; PMCID: PMC8377563.
      View in: PubMed   Mentions: 99     Fields:    
    58. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res. 2021 09 15; 27(18):5123-5130. Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. PMID: 34108177; PMCID: PMC8634828.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    59. TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. J Immunother Cancer. 2021 05; 9(5). de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS. PMID: 33980590; PMCID: PMC8118032.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    60. Reply to R. Kebudi et al. JCO Oncol Pract. 2021 06; 17(6):364. Tsu-Yu Wu J, Kwon DH, Glover M, Henry S, Wood D, Rubin D, Koshkin V, Schapira L, Shah SA. PMID: 33881937.
      View in: PubMed   Mentions:    Fields:    
    61. PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review. Kidney Cancer. 2021; 5(1):31-46. Jang A, Sweeney PL, Barata PC, Koshkin VS. View Publication.
    62. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021 06; 32(6):787-800. Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. PMID: 33746047; PMCID: PMC7972830.
      View in: PubMed   Mentions: 181     Fields:    Translation:HumansCellsPHPublic Health
    63. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. Cancer. 2021 06 15; 127(12):1965-1973. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. PMID: 33690902.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    64. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int. 2021 08; 128(2):196-205. Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P. PMID: 33556233.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    65. Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma. Curr Treat Options Oncol. 2021 01 12; 22(2):15. Christensen BR, Hajja YM, Koshkin V, Barata PC. PMID: 33438115.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    66. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. Eur Urol Oncol. 2021 06; 4(3):464-472. Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. PMID: 33423945; PMCID: PMC8169524.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    67. Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California. JCO Oncol Pract. 2021 Mar; 17(3):e377-e385. Wu JT, Kwon DH, Glover MJ, Henry S, Wood D, Rubin DL, Koshkin VS, Schapira L, Shah SA. PMID: 33332170; PMCID: PMC8462649.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    68. Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer. Cancer Med. 2021 01; 10(1):62-69. Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S, Hope TA. PMID: 33247633; PMCID: PMC7826487.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    69. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Front Oncol. 2020; 10:581189. Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA. PMID: 33194712; PMCID: PMC7642690.
      View in: PubMed   Mentions: 6  
    70. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer. Future Oncol. 2021 Jan; 17(2):137-149. Huddart RA, Siefker-Radtke AO, Balar AV, Bilen MA, Powles T, Bamias A, Castellano D, Khalil MF, Van Der Heijden MS, Koshkin VS, Pook DW, Özgüroglu M, Santiago L, Zhong B, Chien D, Lin W, Tagliaferri MA, Loriot Y. PMID: 32938232.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    71. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. J Urol. 2021 02; 205(2):414-419. Wei XX, Werner L, Teo MY, Rosenberg JE, Koshkin VS, Grivas P, Szabados B, Morrison L, Powles T, Carril-Ajuria L, Castellano D, Velho PI, Hahn NM, McKay RR, Raggi D, Necchi A, Kanesvaran R, Alerasool P, Gaines J, Galsky M, Bellmunt J, Sonpavde G. PMID: 32935617; PMCID: PMC8715311.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    72. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 06 20; 395(10241):1907-1918. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL, COVID-19 and Cancer Consortium. PMID: 32473681; PMCID: PMC7255743.
      View in: PubMed   Mentions: 970     Fields:    Translation:HumansCellsPHPublic Health
    73. Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. Invest New Drugs. 2019 06; 37(3):559-566. Koshkin VS, Mir MC, Barata P, Gul A, Gupta R, Stephenson AJ, Kaouk J, Berglund R, Magi-Galluzzi C, Klein EA, Dreicer R, Garcia JA. PMID: 31037562.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    74. The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape. Transl Cancer Res. 2019 Mar; 8(Suppl 2):S130-S132. Koshkin VS, Basu A, Grivas P. PMID: 35117082; PMCID: PMC8797653.
      View in: PubMed   Mentions: 1  
    75. Systematic Review: Targeting HER2 in Bladder Cancer. Bladder Cancer. 2019; 5(1):1-12. Koshkin VS, O’Donnell P, Yu EY, Grivas P. View Publication.
    76. Translational Cancer Research. The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape. 2018. Koshkin VS, Basu A, Grivas P. View Publication.
    77. Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Ther Adv Urol. 2018 Dec; 10(12):445-454. Koshkin VS, Small EJ. PMID: 30574205; PMCID: PMC6295778.
      View in: PubMed   Mentions: 1  
    78. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clin Cancer Res. 2019 01 01; 25(1):210-221. Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P. PMID: 30327311; PMCID: PMC6333466.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    79. Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2018 10; 16(5):413-419.e1. Barata PC, Mendiratta P, Kotecha R, Gopalakrishnan D, Juloori A, Chao ST, Koshkin V, Ornstein M, Gilligan TD, Wood LS, Rini BI, Angelov L, Garcia JA. PMID: 30172552.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    80. HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. J Clin Invest. 2018 08 01; 128(8):3333-3340. Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S, Tyler A, Berk MP, Hu B, Hwang TH, Figg WD, Peer CJ, Chien C, Koshkin VS, Mendiratta P, Grivas P, Rini B, Garcia J, Auchus RJ, Sharifi N. PMID: 29939161; PMCID: PMC6063492.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    81. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. Prostate. 2018 09; 78(13):1035-1041. Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA. PMID: 29882332.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    82. Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Ther Clin Risk Manag. 2018; 14:1019-1040. Gopalakrishnan D, Koshkin VS, Ornstein MC, Papatsoris A, Grivas P. PMID: 29892196; PMCID: PMC5993034.
      View in: PubMed   Mentions: 31  
    83. Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research. Transl Androl Urol. 2018 Jun; 7(3):504-507. Koshkin VS, Grivas P. PMID: 30050808; PMCID: PMC6043741.
      View in: PubMed   Mentions: 1  
    84. Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. Target Oncol. 2018 06; 13(3):353-361. Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, Garcia JA, Grivas P. PMID: 29623487.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    85. Targeted Oncology. Future Directions of Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer. 2018. Koshkin VS, Grivas P. View Publication.
    86. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. Curr Oncol Rep. 2018 04 11; 20(6):48. Koshkin VS, Grivas P. PMID: 29644490.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    87. Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. Clin Genitourin Cancer. 2018 08; 16(4):e879-e892. Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P. PMID: 29576445.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    88. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer. 2018 01 29; 6(1):9. Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI. PMID: 29378660; PMCID: PMC5789686.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    89. Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. Clin Genitourin Cancer. 2018 04; 16(2):e437-e442. Zahoor H, Elson P, Stephenson A, Haber GP, Kaouk J, Fergany A, Lee B, Koshkin V, Ornstein M, Gilligan T, Garcia JA, Rini B, Grivas P. PMID: 29154041.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    90. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann Oncol. 2017 Oct 01; 28(10):2458-2463. Barata PC, Koshkin VS, Funchain P, Sohal D, Pritchard A, Klek S, Adamowicz T, Gopalakrishnan D, Garcia J, Rini B, Grivas P. PMID: 28945843.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    91. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. Eur Urol Focus. 2019 03; 5(2):242-249. Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K, Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrosp. PMID: 28753897; PMCID: PMC5712487.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    92. Cancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma? Ann Oncol. 2017 04 01; 28(4):680-682. Grivas P, Koshkin VS, Pal SK. PMID: 28328001.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    93. Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. J Clin Oncol. 2016 Oct 20; 34(30):3680-3685. Koshkin VS, Bolejack V, Schwartz LH, Wahl RL, Chugh R, Reinke DK, Zhao B, O JH, Patel SR, Schuetze SM, Baker LH. PMID: 27573658; PMCID: PMC5065114.
      View in: PubMed   Mentions: 10     Fields:    
    94. Emerging therapeutics in refractory renal cell carcinoma. Expert Opin Pharmacother. 2016 Jun; 17(9):1225-32. Koshkin VS, Rini BI. PMID: 27112171.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    95. CAD-associated reader error in CT colonography. Acad Radiol. 2012 Jul; 19(7):801-10. Koshkin VS, Hinshaw JL, Wroblewski K, Dachman AH. PMID: 22537502.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    96. Caspase-mediated cell death predominates following engraftment of neural progenitor cells into traumatically injured rat brain. Brain Res. 2005 Dec 14; 1065(1-2):8-19. Bakshi A, Keck CA, Koshkin VS, LeBold DG, Siman R, Snyder EY, McIntosh TK. PMID: 16309635.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    Vadim's Networks
    Concepts (204)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (71)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.